|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on November 27, 2002; DOI 10.1182/blood-2002-07-2299.
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Division of Hematology and Internal Medicine;
Section of Biostatistics; Division of Endocrinology, Diabetes,
Metabolism, Nutrition, and Internal Medicine; and Department of
Neurology; Mayo Clinic, Rochester, MN.
The POEMS syndrome (coined to refer to polyneuropathy,
organomegaly, endocrinopathy, M protein, and skin changes) remains poorly understood. Ambiguity exists over the features necessary to
establish the diagnosis, treatment efficacy, and prognosis. We
identified 99 patients with POEMS syndrome. Minimal criteria were a
sensorimotor peripheral neuropathy and evidence of a monoclonal plasmaproliferative disorder. To distinguish POEMS from neuropathy associated with monoclonal gammopathy of undetermined significance, additional criteria were included: a bone lesion, Castleman disease, organomegaly (or lymphadenopathy), endocrinopathy, edema (peripheral edema, ascites, or effusions), and skin changes. The median age at
presentation was 51 years; 63% were men. Median survival was 165 months. With the exception of fingernail clubbing
(P = .03) and extravascular volume overload
(P = .04), no presenting feature, including the number of
presenting features, was predictive of survival. Response to therapy
(P < .001) was predictive of survival. Pulmonary
hypertension, renal failure, thrombotic events, and congestive heart
failure were observed and appear to be part of the syndrome. In 18 patients (18%), new disease manifestations developed over time. More
than 50% of patients had a response to radiation, and 22% to 50% had
responses to prednisone and a combination of melphalan and prednisone,
respectively. We conclude that the median survival of patients with
POEMS syndrome is 165 months, independent of the number of syndrome
features, bone lesions, or plasma cells at diagnosis. Additional
features of the syndrome often develop, but the complications of
classic multiple myeloma rarely develop.
(Blood. 2003;101:2496-2506) Associations between plasma cell dyscrasia
and peripheral neuropathy are well recognized.1 One third
to one half of patients with osteosclerotic myeloma have
neuropathy,2-4 and one half of patients with myeloma and
peripheral neuropathy have osteosclerotic lesions.5 These
figures contrast distinctly with the 1% to 8% incidence of neuropathy
in patients with classic multiple myeloma.6,7
In 1956, the interaction of plasma cell dyscrasia and peripheral
neuropathy was shown to be more complex with Crow's1
description of 2 patients with osteosclerotic plasmacytomas with
neuritis and other "striking features," which included clubbing,
skin pigmentation, dusky discoloration of the skin, white fingernails,
mild lymphadenopathy, and ankle edema. Scheinker's autopsy case in
1938 was the first report of what we now call POEMS syndrome,
Crow-Fukase syndrome, PEP syndrome (plasma cell dyscrasia,
endocrinopathy, and polyneuropathy), or Takatsuki
syndrome.8,9 The patient was a 39-year-old man with a
solitary plasmacytoma, sensorimotor polyneuropathy, and localized
patches of thickened and deeply pigmented skin on the chest.3,10 Subsequently, others reported patients with
osteosclerotic myeloma and peripheral neuropathy with organomegaly,
skin changes, endocrinopathy, edema, hypertrichosis, gynecomastia, and
ascites.2-4,9,11-18 In a 1977 review by Iwashita et
al,3 30 patients with osteosclerotic myeloma and
peripheral neuropathy, as compared with 29 patients without peripheral
neuropathy, had a higher incidence of hyperpigmentation, edema, skin
thickening, hepatomegaly, hypertrichosis, and clubbing. In 1980, Bardwick et al19 coined the acronym POEMS to
represent a syndrome characterized by polyneuropathy, organomegaly,
endocrinopathy, M protein, and skin changes. Not represented in the
acronym are several important features, including sclerotic bone
lesions, Castleman disease, papilledema, pleural effusion, edema,
ascites, and thrombocytosis.8,20-22
No single test establishes the diagnosis of POEMS syndrome. Seemingly
disparate signs and symptoms must be linked to establish the diagnosis.
Although several series have been reported,8,19,22 ambiguity exists about the number of features necessary for diagnosis, effective therapies, and prognosis. The interconnections between POEMS
syndrome, osteosclerotic myeloma, and Castleman disease are still under
investigation. Cytokines have been implicated in the pathogenesis of
the disease.23-25 POEMS appears to be mediated by an
imbalance of proinflammatory cytokines. Interleukin-1 In a retrospective review of a single institution's experience, we
defined the minimal criteria required for the diagnosis of POEMS
syndrome, described the natural history of the disease, and studied
whether pulmonary hypertension, restrictive lung disease, thrombosis,
cardiomyopathy, and glomerulonephritis are true associations.
The Mayo Clinic dysproteinemia database was queried for all
patients with POEMS syndrome or osteosclerotic myeloma. One reviewer (A.D.) abstracted data. Through December 1998, 99 patients were identified who met the minimal criteria for study inclusion. The diagnosis had been made at our institution in 80 patients and elsewhere
in 19 patients. All 99 patients had both major criteria and one minor
criterion for the diagnosis of POEMS syndrome (Table 1).
All patients (or their physicians) for whom no follow-up data were
available in the preceding year were contacted. Death certificates were
sought for deceased patients for whom there was inadequate information.
Follow-up data were available for 93 patients (94%). Median follow-up
was 70.6 months (range, 0.2 to 304 months). Twenty-four patients (24%)
were evaluated from 1960 to 1985, 33 (33%) from 1986 to 1990, and 42 (42%) from 1991 to 1998. The Mayo Foundation Institutional Review
Board approved the study in accordance with Minnesota state law.
The definitions of response to treatment were based on both patient and
physician reports of improvement rather than on strictly defined
objective criteria. Patients who had little or no residual neuropathy
and otherwise regained a normal sense of well-being and function were
classified as having had a very good response. Those who had
improvement in their neuropathy but still perceived themselves to have
a significant handicap were classified as having had a good response.
Patients whose deterioration stabilized during or after treatment but
did not derive any subjective or objective improvement were classified
as having stable disease. Patients who continued to deteriorate despite
therapy were deemed refractory.
Curves for overall survival and time to the development of new
syndrome features were plotted according to the method of Kaplan and
Meier31 and were compared by the log-rank
test.32 Survival was calculated from the time of
diagnosis. Prognostic factors for overall survival and risk of
developing additional features were determined by the Cox proportional
hazards model in the analysis of covariates.33 Variables
analyzed in these models include the following: age, sex,
organomegaly, papilledema, skin abnormalities, endocrine
abnormalities, edema, weight loss, lymphadenopathy, Castleman disease,
number of POEMS features, thrombocytosis, hemoglobin level, type of
immunoglobulin heavy chain, bone marrow plasmacytosis, serum M-protein
level, urine M-protein level, number of bone lesions, and type of treatment.
Presenting features
Polyneuropathy Peripheral neuropathy is the dominant clinical feature of this disorder (Table 3). By definition, all patients in this series had a peripheral neuropathy. Although neuropathy is typically the presenting symptom, in the present series 5 patients (5%) had a known plasma cell dyscrasia before the onset of the neuropathy.8,22 All patients in this series had increased cerebrospinal fluid protein, increased cerebrospinal fluid opening pressures, and a normal cell count.8,22 Thirty-one patients (31%) had sural nerve biopsy; in most cases, the findings were those of a demyelinating process with axonal loss.Organomegaly Fifty patients (50%) had organomegaly. Twenty-six patients (26%) had lymphadenopathy. Of these 26, 15 underwent biopsy: 11 had Castleman disease, and 4 had reactive changes. Twenty-four patients (24%) had hepatomegaly, and 22 (22%) had splenomegaly. No patient had massive lymphadenopathy or organomegaly. The percentage of patients with organomegaly in our series seems lower than that in other series (Table 3).Endocrinopathy Endocrine abnormality is a defining feature of POEMS.19 In the present study, 66 patients (67%) had at least one endocrine abnormality at presentation. Later in the course of disease, endocrine abnormalities developed in 7 other patients (7%). Most patients did not have a thorough endocrine evaluation, lowering the reported incidence. Because both diabetes mellitus and hypothyroidism are common endocrine abnormalities, care was taken to assign them as part of the syndrome only if there appeared to be a clear temporal relationship. The overall prevalence of endocrinopathy was similar to that previously reported by others (Table 3).22,34Hypogonadism was most common, though laboratory data were too sparse to determine whether there was primary or secondary failure. Forty-four men (71%) had erectile dysfunction. Twenty-eight of these men had serum testosterone levels measured; all but 4 had low levels. Of those not reporting sexual dysfunction, 5 had low serum testosterone levels. Of the 19 men who had serum prolactin levels measured, none had high levels. Seventeen men had gynecomastia; none of the 4 men tested had high serum estradiol levels. The sexual history of women was less reliably ascertained. Two women had irregular menses, one of whom also had galactorrhea. Serum estradiol levels were normal in all 4 women tested. Among the 25 patients with measured serum prolactin levels, levels were high (range, 26 to 58 µg/mL [26 to 58 ng/L]; normal, less than 23 µg/mL [23 ng/L]) in 3 men and 2 women. Fourteen patients (14%) had hypothyroidism requiring treatment. Another 12 patients (12%) had mild increases in thyroid-stimulating hormone (5.8 to 13.4 mU/L [5.8 to 13.4 µU/mL]; normal, 0.3 to 5.0 mU/L [0.3 to 5.0 µU/mL]) and normal thyroxine levels; these patients were not treated and therefore not considered to have an endocrine abnormality in this series. The hypothyroidism was primary in 9 patients and secondary in 3. In 3 patients, hypothyroidism was the only endocrine abnormality. The remainder had gonadal or adrenal dysfunction or both. In 6 other patients, hypothyroidism developed during the course of disease; they were not included among those considered to have an endocrine abnormality at presentation (Table 3). Three patients (3%) had diabetes mellitus, having high fasting glucose and glycosylated hemoglobin levels. Of the 35 patients who had adrenal-pituitary testing, 16 (16%) had abnormalities of the adrenal-pituitary axis at presentation. In another 5 patients, adrenal insufficiency developed later in the course of disease. In total, 9 patients had primary adrenal dysfunction, 3 had secondary adrenal dysfunction, and 10 had insufficient data to make the distinction. Serum levels of parathyroid hormone were measured in 4 patients and were found to be increased in 3. In one patient hypoparathyroidism was diagnosed 84 months after POEMS syndrome was diagnosed. Monoclonal plasmaproliferative disorder By definition, all patients had evidence of a monoclonal plasmaproliferative disorder. Eighty-four patients (85%) had a detectable monoclonal protein in their serum on analysis by immunofixation. These findings are similar to those of Nakanishi et al,8 who found an M component to be present in 75% of patients. The serum protein electrophoresis patterns of 24 of our patients were normal; patterns of 7 patients appeared polyclonal. Had immunofixation not been done, the monoclonal protein would have been missed in these 31 patients. Although 40 patients had a detectable monoclonal protein in their urine, in only 3 patients did urine screening identify a monoclonal plasmaproliferative disorder that had not been detected in the serum. The quantity of monoclonal protein was small in both serum and urine, with a median serum M-spike of 11 g/L (1.1 g/dL) (range, 0.0 to 41 g/L [4.1 g/dL]; only 7 patients had an M-spike more than 20 g/L [2 g/dL]) (Table 2). The median total urine protein was 100 mg per 24 hours.All patients had a monoclonal Of 90 patients who had a bone marrow biopsy performed, the most common interpretation was "nondiagnostic," with the predominant feature being a hypercellular or "reactive-appearing" marrow. Twenty-one patients had a normal-appearing marrow. Only 4 patients had more than 20% plasma cells; none of these 4 patients had lytic bone disease or anemia. In 25 patients, there was only a slight increase in plasma cells (Tables 2 and 3). Our finding that 14% of patients had a bone marrow plasmacytosis more than 10% is similar to the 5% to 20% previously reported.8,22 Skin changes Skin changes were documented in 67 patients (68%) (Table 3). The most common abnormality was hyperpigmentation (46 patients), followed by acrocyanosis and plethora (19 patients). The latter 2 features were not well-captured in the other large series, but they are described elsewhere.1,8,22,35 Five patients had skin thickening. Multiple hemangiomas were documented in 9 patients; vascular changes similar to those in Kaposi sarcoma were seen in one of these patients. A necrotizing vasculitis along with hyperpigmentation was present in another patient. Of the 26 patients with hypertrichosis, only 5 had no endocrine abnormality, and only 4 had no other skin abnormalities. The hypertrichosis was either generalized or limited to body parts, such as the extremities or face. Twenty-nine patients had 2 or 3 coexistent skin abnormalities. Although white nails can occur in patients with POEMS syndrome, no mention of this finding was made regarding the patients we studied.Edema and effusions On presentation, 29 patients (29%) had some form of extravascular volume overload. Peripheral edema, ascites, and pleural effusions were present in 24, 7, and 3 patients, respectively (Table 3). One patient had a pericardial effusion. The incidence of edema and effusions was lower in our series than in other series; however, if one includes patients in whom edema or effusions developed during the course of disease, the numbers increase to 29, 15, and 9, respectively.Sclerotic bone lesions On presentation, 95 patients had at least one abnormality detected on radiographic bone survey (Table 3). Of the 4 patients not presenting with a bone lesion, all had 4 or 5 features of POEMS syndrome, including a clonal plasmaproliferative disorder. In one patient, a sclerotic bone lesion developed 18 months later, yielding a total of 96 patients (97%) with abnormal findings on bone radiography. Of the patients with abnormal findings, all but 2 had sclerotic bone lesions. The radiographs for these 2 patients could not be located to establish whether there was any element of sclerosis associated with the lytic lesions. These 2 patients had solitary lytic lesions. In our experience, lytic lesions in patients with POEMS syndrome tend to have a sclerotic rim. Forty-nine patients had lesions with mixed sclerotic and lytic components. Forty-three patients had a solitary lesion, 22 had 2 or 3 lesions, and 31 had more than 3 lesions (Table 3). These findings are consistent with those of previous publications.8,22 Twenty-two patients underwent biopsy of a sclerotic lesion; results were diagnostic in 20.Papilledema Papilledema was observed in 29 patients (29%) (Table 3). In other series, papilledema has been observed in 40% to 55% of patients.8,22Other established features Thirty-seven patients (37%) had lost more than 10 pounds of body weight at presentation. Thirty-one patients (31%) complained of significant fatigue. Five patients (5%) had recognized clubbing at diagnosis, one of whom had coincident restrictive lung disease. Patients with clubbing seemed to have more extensive disease: all had organomegaly, endocrinopathy, skin changes, peripheral neuropathy, and plasmaproliferative disorder; in all but one of these patients, additional POEMS features developed over time. Thirteen patients (13%) complained of generalized bone pain or arthralgia; only 3 of these patients had diffuse sclerotic lesions. Fifty-three patients (54%) had thrombocytosis, and 18 (18%) had polycythemia (hemoglobin more than 150 g/L [15 g/dL] in women and more than 170 g/L [17 g/dL] in men).Unusual features Data from case reports and small series suggest that pulmonary hypertension, congestive heart failure, thrombosis, and renal failure may be part of the POEMS syndrome (Table 1).7,29,36-76 In the present series, 47 patients had one or more of these features.Fourteen patients had lung disease other than effusion during the course of their illness; 3 had effusion, one of whom also had other pulmonary manifestations. Five patients had pulmonary hypertension. Five patients had restrictive lung disease. In 4 patients, respiratory failure or insufficiency developed within several months before death; 17% of deaths were due to respiratory failure. Four patients died of complications of renal failure between 34 and 120 months after diagnosis. The renal failure occurred within 6 months before death in 3 patients and 3 years before death in 1. There was associated ascites in 3 of the 4 patients. No renal biopsies were performed. All patients who died of renal failure had coexistent ascites and a capillary leaklike syndrome. Congestive heart failure and cardiomyopathy were among the presenting features in 3 patients. After treatment of the plasma cell dyscrasia with either radiation or combination chemotherapy, cardiac symptoms resolved in all 3 patients. In 4 other patients, congestive heart failure developed at 12, 30, 56, and 192 months. Each of the cardiac events occurred during a POEMS exacerbation. Two patients had pericarditis within a few months of presentation. Twenty-one thrombotic events (10 venous, 11 arterial) occurred in 18 patients. Seven patients had 8 thrombotic events predating their diagnosis with POEMS. Eleven patients had 13 events after diagnosis. Survival and prognostic features Overall median survival was 165 months (Figure 1). Only fingernail clubbing and extravascular volume overload (edema, effusion, or ascites) were prognostic for survival. Patients with clubbing or extravascular volume overload had a median survival of 31 and 79 months, respectively. These variables were independent of each other, and their corresponding proportional hazard ratios for death were 4.0 (P = .03) and 2.1 (P = .04). Patients who received radiation therapy and those who had a very good or good response to treatment also had superior survival (Figure 2).
When we used the criteria of Bardwick et al,19 median
survival for patients with 2, 3, 4, and 5 features at presentation was
more than 174, 85, more than 302, and 96 months, respectively; 29%,
50%, 23%, and 34% of the patients in the respective groups have
died. When we used the 9 major and minor criteria in Table 1, median
survival for patients with 3, 4, 5, 6, 7, 8, and 9 features was more
than 174, 85, more than 302, 49, more than 197, 103, and 50 months,
respectively (P = not significant) (Figure 3); 17%, 47%, 25%, 53%, 25%, 29%,
and 100% of the patients in the respective groups have died. In toto,
35 patients have died (Table 4). The most
commonly identified causes of death were cardiorespiratory failure and
infection. No patient died of classic myeloma
Long-term follow-up of patients with POEMS syndrome Not only are the number of features present at diagnosis not prognostic of survival (Figure 3), but patients often accumulate additional features of POEMS syndrome over time (Table 5). In our cohort, the median time between onset of symptoms and diagnosis was 15 months (range, 3-120 months). The respective median times in months from the initial occurrence of symptoms to diagnosis for patients with 2, 3, 4, and 5 features at presentation were 11 (range, 5-60); 13 (range, 3-60); 15 (range, 3-48); and 21 (range, 3-120). Moreover, during follow-up additional classic POEMS characteristics developed in 18 patients; possible POEMS features (congestive heart failure and thrombosis) developed in 7 other patients.
Seven patients had only 2 of the 5 POEMS features as described by Bardwick et al,19 namely, the monoclonal plasmaproliferative disorder and peripheral neuropathy. All 7 patients had at least 1 osteosclerotic bone lesion; in fact, 6 had more than 1 lesion. Additional POEMS features subsequently developed in 2 (Table 5). Among the 32 patients with 3 features of POEMS, additional features developed in 5 patients 9 to 60 months after the original diagnosis. Among the 31 patients with 4 features of POEMS, other features subsequently developed in 6. Finally, among the 29 patients with all 5 features, other POEMS features developed in 4. Presenting features were evaluated for their value in predicting the development of other POEMS features. On univariate analysis, the only factors predictive of the development of additional POEMS features were a serum M-spike of more than 1 g/dL (P = .04), the presence of a monoclonal protein in the urine (P = .05), and the absence of radiation therapy (P = .02). On multivariate analysis, only the presence of a urinary monoclonal protein was predictive of the development of additional features (proportional hazards, 4.82; confidence interval, 1.71-13.8; P = .003). Among the 18 patients in whom additional POEMS-associated features developed over time, those patients with the fewest POEMS features as described by Bardwick et al19 had the highest risk of additional features developing (29% vs 14%). Therapy Patients were either treated by Mayo Clinic physicians or referred for treatment to their local physicians. Because this was a retrospective analysis, it was difficult to draw firm conclusions regarding therapy. However, we found that 73 patients (74%) had at least some response to therapy (Table 6). Fourteen patients were refractory to the treatments chosen. Sixty-four patients were treated with 70 courses of radiation, 48 with melphalan and prednisone, 15 with alkylator-based combination chemotherapy, 41 with prednisone or dexamethasone alone, 30 with plasmapheresis, and 9 with intravenous immunoglobulin.
A response was defined as stabilization or improvement of symptoms as reported by the patient or the treating physician. Radiation therapy was effective; at least half of patients so treated responded. Only those patients with a solitary lesion or a dominant lesion were treated with radiation. Of the 13 patients who did not respond to radiation, 9 had received less than 4000 cGy. Responses were often inapparent until 3 to 6 months after treatment. Some patients showed continued improvement 1 to 2 years after radiation treatment. Responses of organomegaly and skin changes generally antedated a response of neuropathy. Clinical responses to prednisone and a combination of melphalan and prednisone occurred in approximately 22% to 56% of patients. Patients receiving plasmapheresis, cyclosporine, or azathioprine responded only if they were also receiving prednisone, suggesting that these agents themselves are ineffective. No response was observed with intravenous immunoglobulin.
Clinical features All patients with POEMS syndrome have peripheral neuropathy and a monoclonal plasma cell dyscrasia or Castleman disease. Hepatomegaly, splenomegaly, lymphadenopathy, endocrinopathy, skin changes, papilledema, peripheral edema, ascites, sclerotic bone lesions, clubbing, polycythemia, thrombocytosis, and fatigue are all features of the syndrome.8,22The neuropathy is symmetrical and ascending, with either an insidious or rapidly progressing onset. Patients often describe numbness and dysesthesias followed by a progressive ascending weakness that overshadows the sensory impairment. In most patients, it is the presenting symptom; however, in one series edema preceded neuropathy in 12% of patients and coincided with it in 14%.8 In our series, 5 patients had a known antecedent plasmaproliferative disorder. The neuropathy is seldom painful, and autonomic involvement is rare.5 It is typically a chronic, large-fiber sensorimotor neuropathy. Most authors have not found monoclonal immunoglobulin associated with nerve specimens,8,36,37,77 except for Adams and Said78 and Broussolle et al.79 The estimate that 11% to 30% of POEMS patients have Castleman disease is conservative because many patients do not undergo lymph node biopsy.8,22 The association between the 2 disorders is well recognized but poorly understood.8,22,38,47,65,80-114 Endocrine abnormalities are defining features of the syndrome.19 Primary and secondary hypothyroidism, hypogonadism, adrenocortical insufficiency, and diabetes mellitus have been described.19,22,86,97,115,116 Parathyroid hormone abnormalities were found in 4 of our patients and have been reported previously.2,100,117,118 Papilledema, which occurs in 29% to 55% of patients, may be asymptomatic or may cause headache, transient obscurations of vision, scotomata, enlarged blind spots, or progressive constriction of the visual field.8,22,38,119 Sclerotic bone lesions occur in most patients. They may be solitary or multiple. In the series of Soubrier et al,22 prognosis was significantly better for patients with solitary bone lesions. In our series, survival was independent of the number of bone lesions. However, response to therapy was better in patients with radiated dominant bone lesions. Clubbing may occur in up to 13% of patients.1,120 It is unclear whether the clubbing observed in patients with POEMS syndrome is a function of undiagnosed pulmonary hypertension121; regardless, our data demonstrate that the presence of clubbing bodes a poor prognosis. Minimal criteria for the diagnosis and evolution of disease A table and comparisons of the largest series of patients with the syndrome are provided in "Results." In Table 1 we list the features associated with POEMS and set forth a proposed model of the minimal criteria needed to establish the diagnosis. Relapse and additional new features can occur even in patients who have responded.7,17,35,48,118,122-125 In our series, this occurred in 18% to 25% of patients, depending on whether one considers congestive heart failure and thrombotic abnormalities to be part of the syndrome. New features can develop more than 10 years after the initial presentation.35 We therefore propose the concept that 2 major criteria and at least 1 minor criterion should be met to establish the diagnosis of POEMS syndrome.Survival The prognosis for patients with POEMS has been reported to be poor, with median survivals estimated to be 12 to 33 months.2,8,9 However, this has not been our experience. In the present series, median survival was 165 months. Reports of patients who have had the disease for more than 5 years are not unusual.7,17,35,118,123,125 In one study, 7 of 15 patients were alive for more than 5 years, with 1 patient living for 25 years.126Our data and those of others demonstrate that survival is not affected by the number of POEMS features,22 although clubbing and extravascular volume overload are associated with shorter survival. In the present series, 35 patients have died. Even patients with multiple bone lesions or those with more than 10% plasma cells do not progress to overt multiple myeloma. Bone fractures rarely develop. The neuropathy may be unrelenting and contribute to progressive inanition and eventual cardiorespiratory failure and pneumonia. Stroke and myocardial infarction, which may or may not be related to the POEMS syndrome, also are observed causes of death. Less-recognized features Less-recognized phenomena may be pulmonary hypertension, restrictive lung disease, cardiomyopathy, and an increased incidence of arterial and venous thrombosis.At least 13 cases of pulmonary hypertension in patients with POEMS syndrome have been reported in previous series.36-45 In the present series, we report an additional 5. Moreover, restrictive lung disease was recognized in another 5% of our patients, and 20% of deaths were related to respiratory failure. In a series of 20 patients with POEMS followed up during a 10-year period, 25% had pulmonary hypertension.43 Cardiomyopathy and congestive heart disease were observed in 7 of our patients. These conditions have been reported in 3 other cases.7,42,46 Both arterial and venous thromboses have been described in patients with POEMS syndrome. In our series, there were 18 patients with stroke, myocardial infarction, and Budd-Chiari syndrome. Lesprit et al26 observed 4 of 20 patients to have arterial occlusion. An additional 15 patients with gangrene, ischemia, myocardial infarction, splenic infarcts, and strokes have been reported.47-60 Vasospastic angina,61,62 pulmonary embolism, and Budd-Chiari syndrome also have been described.63,64 In 4 of our patients, renal failure developed as a preterminal event. The renal histologic characteristics of patients with POEMS have been described.29,36,48,65-76 Almost one half of these patients had coexistent Castleman disease. Light-chain deposition is not observed. Instead, membranoproliferative features and evidence of endothelial injury are characteristic.36,48,66,71-73 Treatment strategies Because the pathogenesis of this multisystem disease is unclear, treatment is not standardized. The light chain has been implicated
because less than 5% of patients with POEMS syndrome have monoclonal
 .5,8,9,34,78,104,124,127,128 The hypothesis implicating
vascular endothelial growth
factor25,28,30,37,65,99,126,129-131 eventually may be
validated, providing a uniform target for therapy. To avoid the risk of
systemic alkylator exposure, most would agree that for an isolated
plasmacytoma, radiation is the preferred treatment.3,11,79,120,132 Systemic and skin symptoms tend to respond sooner than do symptoms of neuropathy, with the former beginning to respond within 1 month and the latter within 3 to 6 months. Besides radiation, many strategies have been used, including plasmapheresis, intravenous immunoglobulin, interferon alfa,
corticosteroids, alkylators, azathioprine, autologous stem cell
transplantation, tamoxifen, and transretinoic
acid.3,7,8,11,20,21,48,63,71,79,96,97,100 105-107,118,120,122,125,127,130,132-144
On the basis of our experience and reports in the
literature,105,125,134 neither plasmapheresis nor
intravenous immunoglobulin is effective treatment. Alkylators with or
without corticosteroids are effective in some
patients.7,100,105 High-dose chemotherapy with autologous
stem cell support may be considered.143-146
Screening for the syndrome Screening for POEMS syndrome with serum protein electrophoresis alone is inadequate. Immunofixation of serum and urine and metastatic bone survey are essential for all patients with unexplained peripheral neuropathy. If the index of suspicion is high enough, bone marrow aspirate and biopsy with immunostaining may be required. The predominance of monoclonal cannot be overemphasized. Skin, viscera,
lymph nodes, and optic fundi should be examined carefully. If the
diagnosis is strongly suspected, a thorough endocrine evaluation should
be performed. If the patient has respiratory symptoms, pulmonary
function testing and echocardiography should be performed.
Final comments We propose that the diagnosis of POEMS syndrome be predicated on the presence of major and minor criteria. Two major criteria and at least one minor criterion should be satisfied to differentiate this syndrome from neuropathy associated with monoclonal gammopathy of undetermined significance, myeloma, and Waldenström disease. Primary systemic amyloidosis also should be excluded. The major criteria include a polyneuropathy and a clonal plasmaproliferative disorder (almost always). The minor criteria
include osteosclerotic bone lesions; Castleman disease; papilledema;
organomegaly, including lymphadenopathy; edema, pleural effusion, or
ascites; endocrinopathy; and skin changes.
Survival for patients with POEMS syndrome is better than previously reported, with median survival of 165 months, regardless of how many syndrome features, bone lesions, or plasma cells are present at diagnosis. Patients do not have the usual complications of classic multiple myeloma. Radiation and chemotherapy are the most useful therapies. Ultimately, manipulation of the cytokine milieu may be the treatment of choice.
Submitted July 31, 2002; accepted November 8, 2002.
Prepublished online as Blood First Edition Paper, November 27, 2002; DOI 10.1182/blood- 2002-07-2299.
Supported in part by grants CA62242 and CA91561 from the National Institutes of Health.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Presented in abstract form at the 41st annual meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999. Reprints: Angela Dispenzieri, Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: dispenzieri.angela{at}mayo.edu.
1.
Crow R.
Peripheral neuritis in myelomatosis.
Brit Med J.
1956;2:802-804
2.
Driedger H, Pruzanski W.
Plasma cell neoplasia with osteosclerotic lesions: a study of five cases and a review of the literature.
Arch Intern Med.
1979;139:892-896
3.
Iwashita H, Ohnishi A, Asada M, Kanazawa Y, Kuroiwa Y.
Polyneuropathy, skin hyperpigmentation, edema, and hypertrichosis in localized osteosclerotic myeloma.
Neurology.
1977;27:675-681 4. Mangalik A, Veliath AJ. Osteosclerotic myeloma and peripheral neuropathy: a case report. Cancer. 1971;28:1040-1045[CrossRef][Medline] [Order article via Infotrieve].
5.
Kelly JJ Jr, Kyle RA, Miles JM, Dyck PJ.
Osteosclerotic myeloma and peripheral neuropathy.
Neurology.
1983;33:202-210
6.
Evison G, Evans KT.
Sclerotic bone deposits in multiple myeloma [letter].
Br J Radiol.
1983;56:145 7. Reitan JB, Pape E, Fossa SD, Julsrud OJ, Slettnes ON, Solheim OP. Osteosclerotic myeloma with polyneuropathy. Acta Med Scand. 1980;208:137-144[Medline] [Order article via Infotrieve].
8.
Nakanishi T, Sobue I, Toyokura Y, et al.
The Crow-Fukase syndrome: a study of 102 cases in Japan.
Neurology.
1984;34:712-720 9. Driedger H, Pruzanski W. Plasma cell neoplasia with peripheral polyneuropathy: a study of five cases and a review of the literature. Medicine. 1980;59:301-310[Medline] [Order article via Infotrieve]. 10. Scheinker I. Myelom und Nervensystem: Über eine bisher nicht beschriebene mit eigentümlichen Hautveränderungen einhergehende Polyneuritis bei einem plasmazellulären Myelom des Sternums. Deutsche Zeitschrift für Nervenheilkunde. 1938;147:247-273[CrossRef].
11.
Morley JB, Schwieger AC.
The relation between chronic polyneuropathy and osteosclerotic myeloma.
J Neurol Neurosurg Psychiatry.
1967;30:432-442 12. Shimpo S. Solitary myeloma causing polyneuritis and endocrine disorders [in Japanese]. Nippon Rinsho. 1968;26:2444-2456[Medline] [Order article via Infotrieve]. 13. Mayo CM, Daniels A, Barron KD. Polyneuropathy in the osteosclerotic form of multiple myeloma. Trans Am Neurol Assoc. 1968;93:240-242[Medline] [Order article via Infotrieve]. 14. Fukase M, Kakimatsu T, Nishitani H, et al. Report of a case of solitary plasmacytoma in the abdomen presenting with polyneuropathy and endocrinological disorders [abstract]. Clin Neurol. 1969;9:657.
15.
Imawari M, Akatsuka N, Ishibashi M, Beppu H, Suzuki H.
Syndrome of plasma cell dyscrasia, polyneuropathy, and endocrine disturbances: report of a case.
Ann Intern Med.
1974;81:490-493 16. Getaz P, Handler L, Jacobs P, Tunley I. Osteosclerotic myeloma with peripheral neuropathy. S Afr Med J. 1974;48:1246-1250[Medline] [Order article via Infotrieve]. 17. Waldenström JG, Adner A, Gydell K, Zettervall O. Osteosclerotic "plasmocytoma" with polyneuropathy, hypertrichosis and diabetes. Acta Med Scand. 1978;203:297-303[Medline] [Order article via Infotrieve].
18.
Moya-Mir MS, Martin-Martin F, Barbadillo R, et al.
Plasma cell dyscrasia with polyneuritis and dermato-endocrine alterations: report of a new case outside Japan.
Postgrad Med J.
1980;56:427-430 19. Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome: report on two cases and a review of the literature. Medicine. 1980;59:311-322[Medline] [Order article via Infotrieve]. 20. Milanov I, Georgiev D. Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome. Can J Neurol Sci. 1994;21:60-63[Medline] [Order article via Infotrieve].
21.
Longo G, Emilia G, Torelli U.
Skin changes in POEMS syndrome.
Haematologica.
1999;84:86 22. Soubrier MJ, Dubost JJ, Sauvezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS syndrome. Am J Med. 1994;97:543-553[CrossRef][Medline] [Order article via Infotrieve]. 23. Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome [letter]. Lancet. 1996;347:702[Medline] [Order article via Infotrieve]. 24. Watanabe O, Maruyama I, Arimura K, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve. 1998;21:1390-1397[CrossRef][Medline] [Order article via Infotrieve]. 25. Soubrier M, Dubost JJ, Serre AF, et al. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum. 1997;40:786-787[Medline] [Order article via Infotrieve]. 26. Lesprit P, Authier FJ, Gherardi R, et al. Acute arterial obliteration: a new feature of the POEMS syndrome? Medicine. 1996;75:226-232[Medline] [Order article via Infotrieve]. 27. Soubrier M, Guillon R, Dubost JJ, et al. Arterial obliteration in POEMS syndrome: possible role of vascular endothelial growth factor. J Rheumatol. 1998;25:813-815[Medline] [Order article via Infotrieve]. 28. Feinberg L, Temple D, de Marchena E, Patarca R, Mitrani A. Soluble immune mediators in POEMS syndrome with pulmonary hypertension: case report and review of the literature. Crit Rev Oncog. 1999;10:293-302[Medline] [Order article via Infotrieve]. 29. Soubrier M, Sauron C, Souweine B, et al. Growth factors and proinflammatory cytokines in the renal involvement of POEMS syndrome. Am J Kidney Dis. 1999;34:633-638[Medline] [Order article via Infotrieve]. 30. Hashiguchi T, Arimura K, Matsumuro K, et al. Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome. Muscle Nerve. 2000;23:1051-1056[CrossRef][Medline] [Order article via Infotrieve]. 31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481[CrossRef]. 32. Peto R, Peto J. Asymptotically efficient rank in variant test procedures. J R Stat Soc A. 1972;135:185-198[CrossRef]. 33. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-202.
34.
Takatsuki K, Sanada I.
Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases.
Jpn J Clin Oncol.
1983;13:543-555 35. Sakemi H, Okada H. An autopsy case of Crow-Fukase syndrome which developed 18 years after the first manifestation of plasmacytoma. Intern Med. 1992;31:50-54[Medline] [Order article via Infotrieve]. 36. Viard JP, Lesavre P, Boitard C, et al. POEMS syndrome presenting as systemic sclerosis: clinical and pathologic study of a case with microangiopathic glomerular lesions. Am J Med. 1988;84:524-528[CrossRef][Medline] [Order article via Infotrieve]. 37. Rose C, Zandecki M, Copin MC, et al. POEMS syndrome: report on six patients with unusual clinical signs, elevated levels of cytokines, macrophage involvement and chromosomal aberrations of bone marrow plasma cells. Leukemia. 1997;11:1318-1323[CrossRef][Medline] [Order article via Infotrieve]. 38. Brazis PW, Liesegang TJ, Bolling JP, Kashii S, Trachtman M, Burde RM. When do optic disc edema and peripheral neuropathy constitute poetry? Surv Ophthalmol. 1990;35:219-225[CrossRef][Medline] [Order article via Infotrieve]. 39. Mufti GJ, Hamblin TJ, Gordon J. Melphalan-induced pulmonary fibrosis in osteosclerotic myeloma. Acta Haematol. 1983;69:140-141[CrossRef][Medline] [Order article via Infotrieve]. 40. Ribadeau-Dumas S, Tillie-Leblond I, Rose C, et al. Pulmonary hypertension associated with POEMS syndrome. Eur Respir J. 1996;9:1760-1762[Abstract]. 41. Okura H, Gohma I, Hatta K, Imanaka T. Thiamine deficiency and pulmonary hypertension in Crow-Fukase syndrome. Intern Med. 1995;34:674-675[Medline] [Order article via Infotrieve]. 42. Iwasaki H, Ogawa K, Yoshida H, et al. Crow-Fukase syndrome associated with pulmonary hypertension. Intern Med. 1993;32:556-560[Medline] [Order article via Infotrieve].
43.
Lesprit P, Godeau B, Authier FJ, et al.
Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines.
Am J Respir Crit Care Med.
1998;157:907-911 44. Kishimoto S, Takenaka H, Shibagaki R, Noda Y, Yamamoto M, Yasuno H. Glomeruloid hemangioma in POEMS syndrome shows two different immunophenotypic endothelial cells. J Cutan Pathol. 2000;27:87-92[CrossRef][Medline] [Order article via Infotrieve]. 45. Paciocco G, Bossone E, Erba H, Rubenfire M. Reversible pulmonary hypertension in POEMS syndrome: another etiology of triggered pulmonary vasculopathy? Can J Cardiol. 2000;16:1007-1012[Medline] [Order article via Infotrieve]. 46. Shimizu N, Goya M, Akimoto H, et al. Cardiomyopathy in a case of Crow-Fukase syndrome. Jpn Heart J. 1997;38:877-880[Medline] [Order article via Infotrieve].
47.
Forster A, Muri R.
Recurrent cerebrovascular insult 48. Stewart PM, McIntyre MA, Edwards CR. The endocrinopathy of POEMS syndrome. Scott Med J. 1989;34:520-522[Medline] [Order article via Infotrieve]. 49. Hori T, Tsuboi Y, Okubo R, Hirooka M, Yamada T. Crow-Fukase syndrome associated with Castleman disease showing hypertrophic cranial pachymeningitis and bilateral internal carotid artery occlusion [in Japanese]. Rinsho Shinkeigaku. 1999;39:456-460[Medline] [Order article via Infotrieve]. 50. Manning WJ, Goldberger AL, Drews RE, et al. POEMS syndrome with myocardial infarction: observations concerning pathogenesis and review of the literature. Semin Arthritis Rheum. 1992;22:151-161[CrossRef][Medline] [Order article via Infotrieve]. 51. Solomons RE, Gibbs DD. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes: the POEMS syndrome. J R Soc Med. 1982;75:553-555[Medline] [Order article via Infotrieve]. 52. Semble EL, Challa VR, Holt DA, Pisko EJ. Light and electron microscopic findings in POEMS, or Japanese multisystem syndrome. Arthritis Rheum. 1986;29:286-291[Medline] [Order article via Infotrieve].
53.
Tobin MJ, Fitzgerald MX.
The Japanese plasma cell dyscrasia syndrome: case report and theory of pathogenesis.
Postgrad Med J.
1982;58:786-789
54.
Rushton D.
Peripheral sensorimotor neuropathy associated with a localized myeloma.
Br Med J.
1965;2:203-205 55. Amiel JL, Machover D, Droz JP. Plasma cell dyscrasia with arteriopathy, polyneuropathy, and endocrine syndrome: a Japanese disease in an Italian patient [in French]. Ann Med Interne. 1975;126:745-749[Medline] [Order article via Infotrieve]. 56. Huth M, Gordon D, Verrier ED, Otto CM. Aortic valvular fibroma as a source of systemic emboli in POEMS syndrome. J Am Soc Echocardiogr. 1991;4:401-404[Medline] [Order article via Infotrieve]. 57. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-1987. A 59-year-old woman with progressive polyneuropathy and monoclonal gammopathy. N Engl J Med. 1987;316:606-618[Medline] [Order article via Infotrieve]. 58. Virmani R, Popovsky MA, Roberts WC. Thrombocytosis, coronary thrombosis and acute myocardial infarction. Am J Med. 1979;67:498-506[CrossRef][Medline] [Order article via Infotrieve]. 59. Zenone T, Bastion Y, Salles G, et al. POEMS syndrome, arterial thrombosis and thrombocythaemia. J Intern Med. 1996;240:107-109[CrossRef][Medline] [Order article via Infotrieve].
60.
Bova G, Pasqui AL, Saletti M, Bruni F, Auteri A.
POEMS syndrome with vascular lesions: a role for interleukin-1 61. Mochizuki Y, Yoshihashi H, Oishi M, et al. Crow-Fukase syndrome: a case associated with vasospastic angina. Acta Neurol. 1994;16:170-176[Medline] [Order article via Infotrieve]. 62. Kato T, Kaneko E, Numano F, et al. Vasospastic angina in Crow-Fukase syndrome. Am Heart J. 1992;124:505-507[Medline] [Order article via Infotrieve].
63.
Kuwabara S, Hattori T, Shimoe Y, Kamitsukasa I.
Long term melphalan-prednisolone chemotherapy for POEMS syndrome.
J Neurol Neurosurg Psychiatry.
1997;63:385-387 64. Wong VA, Wade NK. POEMS syndrome: an unusual cause of bilateral optic disk swelling. Am J Ophthalmol. 1998;126:452-454[CrossRef][Medline] [Order article via Infotrieve]. 65. Nakazawa K, Itoh N, Shigematsu H, Koh CS. An autopsy case of Crow-Fukase (POEMS) syndrome with a high level of IL-6 in the ascites: special reference to glomerular lesions. Acta Pathol Jpn. 1992;42:651-656[Medline] [Order article via Infotrieve].
66.
Navis GJ, Dullaart RP, Vellenga E, Elema JD, de Jong PE.
Renal disease in POEMS syndrome: report on a case and review of the literature.
Nephrol Dial Transplant.
1994;9:1477-1481 67. Nakamoto Y, Imai H, Yasuda T, Asakura K, Miura AB, Nishimura S. Mesangiolytic glomerulonephritis associated with Takatsuki's syndrome: an analysis of five renal biopsy specimens. Hum Pathol. 1989;20:243-251[CrossRef][Medline] [Order article via Infotrieve].
68.
Nakamoto Y, Imai H, Yasuda T, Wakui H, Miura AB.
A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome.
Nephrol Dial Transplant.
1999;14:2370-2378 69. Fukatsu A, Ito Y, Yuzawa Y, et al. A case of POEMS syndrome showing elevated serum interleukin 6 and abnormal expression of interleukin 6 in the kidney. Nephron. 1992;62:47-51[Medline] [Order article via Infotrieve]. 70. Fukatsu A, Tamai H, Nishikawa K, et al. The kidney disease of Crow-Fukase (POEMS) syndrome: a clinico-pathological study of four cases. Clin Nephrol. 1991;36:76-82[Medline] [Order article via Infotrieve]. 71. Sano M, Terasaki T, Koyama A, Narita M, Tojo S. Glomerular lesions associated with the Crow-Fukase syndrome. Virchows Arch A Pathol Anat Histopathol. 1986;409:3-9[CrossRef][Medline] [Order article via Infotrieve]. 72. Takazoe K, Shimada T, Kawamura T, et al. Possible mechanism of progressive renal failure in Crow-Fukase syndrome. Clin Nephrol. 1997;47:66-67[Medline] [Order article via Infotrieve]. 73. Mizuiri S, Mitsuo K, Sakai K, et al. Renal involvement in POEMS syndrome. Nephron. 1991;59:153-156[Medline] [Order article via Infotrieve]. 74. Kubota T, Yoshizawa N, Takeuchi A, Niwa H. Microangiopathic hypothesis of POEMS tissue lesions. Clin Nephrol. 1992;38:115-118[Medline] [Order article via Infotrieve]. 75. Modesto-Segonds A, Rey JP, Orfila C, Huchard G, Suc JM. Renal involvement in POEMS syndrome. Clin Nephrol. 1995;43:342-345[Medline] [Order article via Infotrieve]. 76. Fam AG, Rubenstein JD, Cowan DH. POEMS syndrome: study of a patient with proteinuria, microangiopathic glomerulopathy, and renal enlargement. Arthritis Rheum. 1986;29:233-241[Medline] [Order article via Infotrieve]. 77. Bergouignan FX, Massonnat R, Vital C, et al. Uncompacted lamellae in three patients with POEMS syndrome. Eur Neurol. 1987;27:173-181[Medline] [Order article via Infotrieve].
78.
Adams D, Said G.
Ultrastructural characterisation of the M protein in nerve biopsy of patients with POEMS syndrome.
J Neurol Neurosurg Psychiatry.
1998;64:809-812 79. Broussolle E, Vighetto A, Bancel B, Confavreux C, Pialat J, Aimard G. P.O.E.M.S. syndrome with complete recovery after treatment of a solitary plasmocytoma. Clin Neurol Neurosurg. 1991;93:165-170[CrossRef][Medline] [Order article via Infotrieve]. 80. Shirabe S, Kishikawa M, Mine M, Miyazaki T, Kuratsune H, Tobinaga K. Crow-Fukase syndrome associated with extramedullary plasmacytoma. Jpn J Med. 1991;30:64-66[Medline] [Order article via Infotrieve]. 81. Thajeb P, Chee CY, Lo SF, Lee N. The POEMS syndrome among Chinese: association with Castleman's disease and some immunological abnormalities. Acta Neurol Scand. 1989;80:492-500[Medline] [Order article via Infotrieve]. 82. Papo T, Soubrier M, Marcelin AG, et al. Human herpesvirus 8 infection, Castleman's disease and POEMS syndrome. Br J Haematol. 1999;104:932-933[CrossRef][Medline] [Order article via Infotrieve]. 83. Vital C, Gherardi R, Vital A, et al. Uncompacted myelin lamellae in polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes syndrome: ultrastructural study of peripheral nerve biopsy from 22 patients. Acta Neuropathol. 1994;87:302-307[Medline] [Order article via Infotrieve]. 84. Yang SG, Cho KH, Bang YJ, Kim CW. A case of glomeruloid hemangioma associated with multicentric Castleman's disease. Am J Dermatopathol. 1998;20:266-270[CrossRef][Medline] [Order article via Infotrieve]. 85. Kobayashi H, Ii K, Sano T, Sakaki A, Hizawa K, Ogushi F. Plasma-cell dyscrasia with polyneuropathy and endocrine disorders associated with dysfunction of salivary glands. Am J Surg Pathol. 1985;9:759-763[CrossRef][Medline] [Order article via Infotrieve]. 86. Bitter MA, Komaiko W, Franklin WA. Giant lymph node hyperplasia with osteoblastic bone lesions and the POEMS (Takatsuki's) syndrome. Cancer. 1985;56:188-194[CrossRef][Medline] [Order article via Infotrieve]. 87. Lapresle J, Lacroix-Ciaudo C, Reynes M, Madoule P. Crow-Fukase syndrome (POEMS syndrome) and osseous mastocytosis secondary to Castleman's angiofollicular lymphoid hyperplasia [in French]. Rev Neurol. 1986;142:731-737[Medline] [Order article via Infotrieve]. 88. Gherardi R, Baudrimont M, Kujas M, et al. Pathological findings in three non-Japanese patients with the POEMS syndrome. Virchows Arch A Pathol Anat Histopathol. 1988;413:357-365[CrossRef][Medline] [Order article via Infotrieve]. 89. Dworak O, Tschubel K, Zhou H, Meybehm M. Angiofollicular lymphatic hyperplasia with plasmacytoma and polyneuropathy: a case report with immunohistochemical study [in German]. Klin Wochenschr. 1988;66:591-595[CrossRef][Medline] [Order article via Infotrieve].
90.
Rolon PG, Audouin J, Diebold J, Rolon PA, Gonzalez A.
Multicentric angiofollicular lymph node hyperplasia associated with a solitary osteolytic costal IgG 91. Carcaterra A, Santini R, Sozzi G, Zuccoli E. Crow-Fukase syndrome (POEMS syndrome): the first Italian presentation of a case and review of the literature [in Italian]. G Ital Dermatol Venereol. 1990;125:97-103[Medline] [Order article via Infotrieve]. 92. Chan JK, Fletcher CD, Hicklin GA, Rosai J. Glomeruloid hemangioma: a distinctive cutaneous lesion of multicentric Castleman's disease associated with POEMS syndrome. Am J Surg Pathol. 1990;14:1036-1046[Medline] [Order article via Infotrieve]. 93. Munoz G, Geijo P, Moldenhauer F, Perez-Moro E, Razquin J, Piris MA. Plasmacellular Castleman's disease and POEMS syndrome. Histopathology. 1990;17:172-174[Medline] [Order article via Infotrieve].
94.
Gherardi RK, Malapert D, Degos JD.
Castleman disease-POEMS syndrome overlap.
Ann Intern Med.
1991;114:520-521 95. Myers BM, Miralles GD, Taylor CA, Gastineau DA, Pisani RJ, Talley NJ. POEMS syndrome with idiopathic flushing mimicking carcinoid syndrome. Am J Med. 1991;90:646-648[Medline] [Order article via Infotrieve]. 96. Coto V, Auletta M, Oliviero U, et al. POEMS syndrome: an Italian case with diagnostic and therapeutic implications. Ann Ital Med Int. 1991;6:416-419[Medline] [Order article via Infotrieve]. 97. Bosco J, Pathmanathan R. POEMS syndrome, osteosclerotic myeloma and Castleman's disease: a case report. Aust N Z J Med. 1991;21:454-456[Medline] [Order article via Infotrieve]. 98. Mandler RN, Kerrigan DP, Smart J, Kuis W, Villiger P, Lotz M. Castleman's disease in POEMS syndrome with elevated interleukin-6. Cancer. 1992;69:2697-2703[CrossRef][Medline] [Order article via Infotrieve]. 99. Emile C, Danon F, Fermand JP, Clauvel JP. Castleman disease in POEMS syndrome with elevated interleukin-6 [letter]. Cancer. 1993;71:874[Medline] [Order article via Infotrieve]. 100. Judge MR, McGibbon DH, Thompson RP. Angioendotheliomatosis associated with Castleman's lymphoma and POEMS syndrome. Clin Exp Dermatol. 1993;18:360-362[CrossRef][Medline] [Order article via Infotrieve]. 101. Del Rio R, Alsina M, Monteagudo J, et al. POEMS syndrome and multiple angioproliferative lesions mimicking generalized histiocytomas. Acta Derm Venereol. 1994;74:388-390[Medline] [Order article via Infotrieve]. 102. Bhatia M, Maheshwari MC. Angiofollicular lymphoid hyperplasia presenting as POEMS syndrome. J Assoc Physicians India. 1994;42:751-752[Medline] [Order article via Infotrieve]. 103. Adelman HM, Cacciatore ML, Pascual JF, Mike JM, Alberts WM, Wallach PM. Case report: Castleman disease in association with POEMS. Am J Med Sci. 1994;307:112-114[Medline] [Order article via Infotrieve]. 104. Pareyson D, Marazzi R, Confalonieri P, Mancardi GL, Schenone A, Sghirlanzoni A. The POEMS syndrome: report of six cases. Ital J Neurol Sci. 1994;15:353-358[CrossRef][Medline] [Order article via Infotrieve]. 105. Ku A, Lachmann E, Tunkel R, Nagler W. Severe polyneuropathy: initial manifestation of Castleman's disease associated with POEMS syndrome. Arch Phys Med Rehabil. 1995;76:692-694[CrossRef][Medline] [Order article via Infotrieve]. 106. Huang CC, Chu CC. Poor response to intravenous immunoglobulin therapy in patients with Castleman's disease and the POEMS syndrome. J Neurol. 1996;243:726-727[CrossRef][Medline] [Order article via Infotrieve]. 107. Chang YJ, Huang CC, Chu CC. Intravenous immunoglobulin therapy in POEMS syndrome: a case report. Zhonghua Yi Xue Za Zhi. 1996;58:366-369[Medline] [Order article via Infotrieve]. 108. Belec L, Salmon-Ceron D, Blanche P, Dreyfus F, Zuber M, Sicard D. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes), multicentric Castleman disease, renal chromophobe carcinoma and herpes virus type 8 infection [in French]. Ann Pathol. 1999;19:373-374[Medline] [Order article via Infotrieve].
109.
Belec L, Mohamed AS, Authier FJ, et al.
Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease.
Blood.
1999;93:3643-3653 110. Belec L, Authier FJ, Mohamed AS, Soubrier M, Gherardi RK. Antibodies to human herpesvirus 8 in POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome with multicentric Castleman's disease. Clin Infect Dis. 1999;28:678-679[Medline] [Order article via Infotrieve]. 111. Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978;69:86-90[Medline] [Order article via Infotrieve]. 112. Hineman VL, Phyliky RL, Banks PM. Angiofollicular lymph node hyperplasia and peripheral neuropathy: association with monoclonal gammopathy. Mayo Clin Proc. 1982;57:379-382[Medline] [Order article via Infotrieve].
113.
Black DA, Forgacs I, Davies DR, Thompson RP.
Pseudotumour cerebri in a patient with Castleman's disease.
Postgrad Med J.
1988;64:217-219
114.
Feigert JM, Sweet DL, Coleman M, et al.
Multicentric angiofollicular lymph node hyperplasia with peripheral neuropathy, pseudotumor cerebri, IgA dysproteinemia, and thrombocytosis in women: a distinct syndrome.
Ann Intern Med.
1990;113:362-367 115. Sasano T, Sakurai SI, Hara Y. Improvement in gonadotropin secretion after corticosteroid therapy in a case of POEMS syndrome. Endocr J. 1998;45:413-419[Medline] [Order article via Infotrieve]. 116. Shichiri M, Iwashina M, Imai T, Marumo F, Hirata Y. Abnormal FSH hypersecretion as an endocrinological manifestation of POEMS syndrome. Endocr J. 1998;45:131-134[Medline] [Order article via Infotrieve]. 117. Ludescher C, Grunewald K, Fend F, Dietze O, Thaler J, Schmid KW. Osteosclerotic myeloma with polyneuropathy and hypocalcemia. Blut. 1989;58:207-210[CrossRef][Medline] [Order article via Infotrieve]. 118. Cabezas-Agricola JM, Lado-Abeal JJ, Otero- Anton E, Sanchez-Leira J, Cabezas-Cerrato J. Hypoparathyroidism in POEMS syndrome. Lancet. 1996;347:701-702[CrossRef][Medline] [Order article via Infotrieve]. 119. Bolling JP, Brazis PW. Optic disk swelling with peripheral neuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS syndrome). Am J Ophthalmol. 1990;109:503-510[Medline] [Order article via Infotrieve].
120.
Davis LE, Drachman DB.
Myeloma neuropathy: successful treatment of two patients and review of cases.
Arch Neurol.
1972;27:507-511 121. Martinez-Lavin M, Vargas AS, Cabre J, et al. Features of hypertrophic osteoarthropathy in patients with POEMS syndrome: a metaanalysis. J Rheumatol. 1997;24:2267-2268[Medline] [Order article via Infotrieve]. 122. Crisci C, Barbieri F, Parente D, Pappone N, Caruso G. POEMS syndrome: follow-up study of a case. Clin Neurol Neurosurg. 1992;94:65-68[CrossRef][Medline] [Order article via Infotrieve]. 123. Rongioletti F, Gambini C, Lerza R. Glomeruloid hemangioma: a cutaneous marker of POEMS syndrome. Am J Dermatopathol. 1994;16:175-178[Medline] [Order article via Infotrieve]. 124. Simmons Z, Wald J, Albers JW, Feldman EL. The natural history of a "benign" rib lesion in a patient with a demyelinating polyneuropathy and an unusual variant of POEMS syndrome. Muscle Nerve. 1994;17:1055-1059[CrossRef][Medline] [Order article via Infotrieve]. 125. Silberstein LE, Duggan D, Berkman EM. Therapeutic trial of plasma exchange in osteosclerotic myeloma associated with the POEMS syndrome. J Clin Apheresis. 1985;2:253-257[Medline] [Order article via Infotrieve].
126.
Gherardi RK, Belec L, Soubrier M, et al.
Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome.
Blood.
1996;87:1458-1465 127. Saida K, Kawakami H, Ohta M, Iwamura K. Coagulation and vascular abnormalities in Crow-Fukase syndrome. Muscle Nerve. 1997;20:486-492[CrossRef][Medline] [Order article via Infotrieve]. 128. Miralles GD, O'Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy: the spectrum of POEMS syndrome. N Engl J Med. 1992;327:1919-1923[Abstract]. 129. Hitoshi S, Suzuki K, Sakuta M. Elevated serum interleukin-6 in POEMS syndrome reflects the activity of the disease. Intern Med. 1994;33:583-587[Medline] [Order article via Infotrieve]. 130. Orefice G, Morra VB, De Michele G, et al. POEMS syndrome: clinical, pathological and immunological study of a case. Neurol Res. 1994;16:477-480[Medline] [Order article via Infotrieve]. 131. Saida K, Ohta M, Kawakami H, Saida T. Cytokines and myelin antibodies in Crow-Fukase syndrome. Muscle Nerve. 1996;19:1620-1622[CrossRef][Medline] [Order article via Infotrieve]. 132. Philips ED, el-Mahdi AM, Humphrey RL, Furlong MB Jr. The effect of the radiation treatment on the polyneuropathy of multiple myeloma. J Can Assoc Radiol. 1972;23:103-106[Medline] [Order article via Infotrieve].
133.
Ako S, Kaneko Y, Higuchi M, et al.
Crow-Fukase syndrome: immunoadsorption plasmapheresis effectively lowers elevated interleukin-6 concentration.
Nephrol Dial Transplant.
1999;14:419-422 134. Atsumi T, Kato K, Kurosawa S, Abe M, Fujisaku A. A case of Crow-Fukase syndrome with elevated soluble interleukin-6 receptor in cerebrospinal fluid: response to double-filtration plasmapheresis and corticosteroids. Acta Haematol. 1995;94:90-94[Medline] [Order article via Infotrieve]. 135. Benito-Leon J, Lopez-Rios F, Rodriguez-Martin FJ, Madero S, Ruiz J. Rapidly deteriorating polyneuropathy associated with osteosclerotic myeloma responsive to intravenous immunoglobulin and radiotherapy. J Neurol Sci. 1998;158:113-117[CrossRef][Medline] [Order article via Infotrieve]. 136. Henze T, Krieger G. Combined high-dose 7S-IgG and dexamethasone is effective in severe polyneuropathy of the POEMS syndrome. J Neurol. 1995;242:482-483[CrossRef][Medline] [Order article via Infotrieve]. 137. Rotta FT, Bradley WG. Marked improvement of severe polyneuropathy associated with multifocal osteosclerotic myeloma following surgery, radiation, and chemotherapy. Muscle Nerve. 1997;20:1035-1037[CrossRef][Medline] [Order article via Infotrieve]. 138. Donofrio PD, Albers JW, Greenberg HS, Mitchell BS. Peripheral neuropathy in osteosclerotic myeloma: clinical and electrodiagnostic improvement with chemotherapy. Muscle Nerve. 1984;7:137-141[CrossRef][Medline] [Order article via Infotrieve]. 139. Parra R, Fernandez JM, Garcia-Bragado F, Bueno J, Biosca M. Successful treatment of peripheral neuropathy with chemotherapy in osteosclerotic myeloma. J Neurol. 1987;234:261-263[CrossRef][Medline] [Order article via Infotrieve]. 140. Antela Lopez A, Requena Caballero I, Masa Vazquez L, Antela Carrera C, Barrio Gomez E. Polyneuropathy associated with osteosclerotic myeloma: excellent response to chemotherapy [in Spanish]. Neurologia. 1990;5:102-106[Medline] [Order article via Infotrieve]. 141. Rousseau JJ, Franck G, Grisar T, Reznik M, Heynen G, Salmon J. Osteosclerotic myeloma with polyneuropathy and ectopic secretion of calcitonin. Eur J Cancer. 1978;14:133-140[Medline] [Order article via Infotrieve].
142.
Reulecke M, Dumas M, Meier C.
Specific antibody activity against neuroendocrine tissue in a case of POEMS syndrome with IgG gammopathy.
Neurology.
1988;38:614-616 143. Rovira M, Carreras E, Bladé J, et al. Dramatic improvement of POEMS syndrome following autologous haematopoietic cell transplantation. Br J Haematol. 2001;115:373-375[CrossRef][Medline] [Order article via Infotrieve]. 144. Hogan WJ, Lacy MQ, Wiseman GA, Fealey RD, Dispenzieri A, Gertz MA. Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2001;28:305-309[CrossRef][Medline] [Order article via Infotrieve]. 145. Dispenzieri A, Lacy MQ, Litzow MR, et al. Peripheral blood stem cell transplant (PBSCT) in patients with POEMS syndrome [abstract]. Blood. 2001;98:391b.
146.
Jaccard A, Royer B, Bordessoule D, Brouet JC, Fermand JP.
High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome.
Blood.
2002;99:3057-3059
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. A. Dupont, A. Dispenzieri, M. L. Mauermann, A. A. Rabinstein, and R. D. Brown Jr Cerebral infarction in POEMS syndrome: Incidence, risk factors, and imaging characteristics Neurology, October 20, 2009; 73(16): 1308 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung Review: Pathogenesis and treatment of immune-mediated neuropathies Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281. [Abstract] [PDF]
|
|
|
|
|
|
S. Kuwabara, S. Misawa, K. Kanai, Y. Suzuki, Y. Kikkawa, S. Sawai, T. Hattori, M. Nishimura, and C. Nakaseko Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome Neurology, November 18, 2008; 71(21): 1691 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Kuwabara, S Misawa, K Kanai, S Sawai, T Hattori, M Nishimura, and C Nakaseko Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome J. Neurol. Neurosurg. Psychiatry, November 1, 2008; 79(11): 1255 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kojima, N. Nakamura, N. Tsukamoto, Y. Otuski, K. Shimizu, H. Itoh, S. Kobayashi, H. Kobayashi, T. Murase, N. Masawa, et al. Clinical Implications of Idiopathic Multicentric Castleman Disease Among Japanese: A Report of 28 Cases International Journal of Surgical Pathology, October 1, 2008; 16(4): 391 - 398. [Abstract] [PDF]
|
|
|
|
|
|
H Koike, M Iijima, K Mori, M Yamamoto, N Hattori, H Watanabe, F Tanaka, M Doyu, and G Sobue Neuropathic pain correlates with myelinated fibre loss and cytokine profile in POEMS syndrome J. Neurol. Neurosurg. Psychiatry, October 1, 2008; 79(10): 1171 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Abe, C. Nakaseko, M. Takeuchi, H. Tanaka, C. Ohwada, E. Sakaida, Y. Takeda, K. Oda, S. Ozawa, N. Shimizu, et al. Restrictive usage of monoclonal immunoglobulin {lambda} light chain germline in POEMS syndrome Blood, August 1, 2008; 112(3): 836 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Allam, C. C. Kennedy, T. R. Aksamit, and A. Dispenzieri Pulmonary Manifestations in Patients With POEMS Syndrome: A Retrospective Review of 137 Patients Chest, April 1, 2008; 133(4): 969 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-Y. Dietrich and M. A. Duchosal Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome Ann. Onc., March 1, 2008; 19(3): 595 - 595. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Korbet and S. Bonsib A Case of Polyneuropathy and Proteinuria Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 624 - 636. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Y. Gandhi, R. Basu, A. Dispenzieri, A. Basu, V. M. Montori, and M. D. Brennan Endocrinopathy in POEMS Syndrome: The Mayo Clinic Experience Mayo Clin. Proc., July 1, 2007; 82(7): 836 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Merlini and M. J. Stone Dangerous small B-cell clones Blood, October 15, 2006; 108(8): 2520 - 2530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Rajkumar, A. Dispenzieri, and R. A. Kyle Monoclonal Gammopathy of Undetermined Significance, Waldenstrom Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment Mayo Clin. Proc., May 1, 2006; 81(5): 693 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Dyck, J. Engelstad, and A. Dispenzieri Vascular endothelial growth factor and POEMS Neurology, January 10, 2006; 66(1): 10 - 12. [Full Text] [PDF]
|
|
|
|
|
|
S. Kuwabara, S. Misawa, K. Kanai, Y. Kikkawa, M. Nishimura, C. Nakaseko, R. K. Cho, and T. Hattori Autologous peripheral blood stem cell transplantation for POEMS syndrome Neurology, January 10, 2006; 66(1): 105 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Dogan, Y Beyazit, A Shorbagi, S Koklu, S Ustunel, N Guler, and A Uner Gastrointestinal involvement in POEMS syndrome: a novel clinical manifestation Postgrad. Med. J., September 1, 2005; 81(959): e12 - e12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Scarlato, S. C. Previtali, M. Carpo, D. Pareyson, C. Briani, R. Del Bo, E. Nobile-Orazio, A. Quattrini, and G. P. Comi Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis Brain, August 1, 2005; 128(8): 1911 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Badros, N. Porter, and A. Zimrin Bevacizumab therapy for POEMS syndrome Blood, August 1, 2005; 106(3): 1135 - 1135. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dispenzieri POEMS Syndrome Hematology, January 1, 2005; 2005(1): 360 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dispenzieri, A. Moreno-Aspitia, G. A. Suarez, M. Q. Lacy, G. Colon-Otero, A. Tefferi, M. R. Litzow, V. Roy, W. J. Hogan, R. A. Kyle, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature Blood, November 15, 2004; 104(10): 3400 - 3407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yaqub, K. G. Moder, and M. Q. Lacy Severe, Reversible Pulmonary Hypertension in a Patient With Monoclonal Gammopathy and Features of Dermatomyositis Mayo Clin. Proc., May 1, 2004; 79(5): 687 - 689. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Di Napoli and A. Arakelyan POEMS Syndrome, Fibrinogen, and Ischemic Stroke: A Critical Point of View Arch Neurol, January 1, 2004; 61(1): 155 - 155. [Full Text] [PDF]
|
|
|
|
|
|
K. L. McClain, Y. Natkunam, and S. H. Swerdlow Atypical Cellular Disorders Hematology, January 1, 2004; 2004(1): 283 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kuwabara, S. Misawa, K. Kanai, Y. Kikkawa, M. Nishimura, C. Nakaseko, R. K. Cho, and T. Hattori Autologous peripheral blood stem cell transplantation for POEMS syndrome Neurology, January 10, 2006; 66(1): 105 - 107. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
(IL-1
inconsistently have been reported to be increased in association with the syndrome.
that is, progressive
bone marrow failure or hypercalcemia. All patients who died of renal
failure had coexistent ascites and a capillary leaklike syndrome.
